<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://www.rmjkol.cn/news/76931792056694914</loc>
    <news:news>
      <news:publication>
        <news:name>人民健康在线</news:name>
        <news:language>zh-cn</news:language>
      </news:publication>
      <news:publication_date>2026-11-06T06:27:34.000Z</news:publication_date>
      <news:title>高剂量伏美替尼强效抑制EGFR PACC突变，G719A突变患者1个月实现PR，PFS已达两年！</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.rmjkol.cn/news/62581792056833502</loc>
    <news:news>
      <news:publication>
        <news:name>人民健康在线</news:name>
        <news:language>zh-cn</news:language>
      </news:publication>
      <news:publication_date>2026-11-06T06:26:50.000Z</news:publication_date>
      <news:title>极速缩瘤！看240mg伏美替尼如何一线突破EGFR PACC复合突变（G719X + S768I）</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.rmjkol.cn/news/66611792057129255</loc>
    <news:news>
      <news:publication>
        <news:name>人民健康在线</news:name>
        <news:language>zh-cn</news:language>
      </news:publication>
      <news:publication_date>2026-11-06T06:24:49.000Z</news:publication_date>
      <news:title>二代TKI不耐受，高龄EGFR PACC合并TP53突变换用高剂量伏美替尼实现18个月超长PFS！</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://www.rmjkol.cn/news/71811792056984770</loc>
    <news:news>
      <news:publication>
        <news:name>人民健康在线</news:name>
        <news:language>zh-cn</news:language>
      </news:publication>
      <news:publication_date>2026-11-06T06:23:11.000Z</news:publication_date>
      <news:title>伏美替尼治疗EGFR PACC突变持续有效，G719A复合突变患者实现34个月超长OS，彰显“高效低毒”优势！</news:title>
    </news:news>
  </url>
</urlset>
